Background
The current ecosystem for RDs in Chile
The Chilean National Healthcare System
Name | Disease(s) or tests | Target Population | Coverage |
---|---|---|---|
Explicit Guarantees in Health GES (Law N° 19,966) [22] | • Hemophilia • Cystic Fibrosis | Individuals with suspected or confirmed diagnosis | Diagnostic confirmation (excludes molecular diagnosis and genetic counseling), follow up and therapies |
Coverage for High Cost medications and devices (Law 20.850 “Ley Ricarte Soto”) [20] | • Mucopolysaccharidoses types I, II, VI • Tyrosinemia Type I • Gaucher Disease • Fabry Disease • Hereditary Angioedema • Pancreatic neuroendocrine tumors • Generalized dystonia • Multiple sclerosis • Primary immunodeficiency • Huntington disease • Epidermolysis bullosa • Amyotrophic lateral sclerosis • Bilateral severe-to-profound sensorineural hearing loss • Unresectable or metastatic gastrointestinal stromal tumors | Individuals with suspected or confirmed diagnosis | Specific high cost medications |
Newborn screening Program [23] | • Phenylketonuria | All newborns | Screening, confirmation, follow up, dietary interventions |
Expanded newborn screening pilot [24] | • Cystic fibrosis • Other inborn errors of metabolism | All newborns | Under evaluation |
Clinical services and access to diagnosis and therapy
Name | Disease(s) or tests | Target Population | Coverage |
---|---|---|---|
Laboratory diagnostic confirmation (FONASA): Karyotype and single probe FISH [29] | • Congenital anomalies • Cognitive disabilities • Recurrent miscarriage and others | Individuals with suspected chromosomal abnormalities | Testing price, according to public or private insurance. |
Laboratory diagnostic confirmation (FONASA): MLPA [29] | • 22q11 microdeletion syndrome • Williams syndrome • Charcot-Marie-Tooth type 1A • Simpson-Golabi-Behmel syndrome • Coffin- Siris syndrome • X-linked ichthyosis • Other recurrent microdeletion and microduplication syndromes | Individuals with suspected sub microscopic chromosomal abnormalities | Testing price, according to public or private insurance. |
Laboratory diagnostic confirmation (FONASA): MS-MLPA [29] | • Prader–Willi syndrome • Angelman syndrome • Silver-Russell syndrome • Beckwith-Wiedemann syndrome | Individuals with suspected chromosomal methylation abnormalities | Testing price, according to public or private insurance. |
Laboratory diagnostic confirmation (FONASA): Sanger sequencing [29] | • Up to 5 amplicons for molecular confirmation of pathogenic/likely pathogenic single nucleotide variants in known genes | Individuals with suspected monogenic conditions due to pathogenic or likely pathogenic variants in known genes | Testing price, according to public or private insurance. |
Economic prioritization criteria for RDs
Regulation
Patient groups
Research
Charting the way forward
- Proposal 1. To establish a national centralized registry of RD patients to obtain specific local as well as integral grouped national evidence, including epidemiology, but also social and economic impact and evaluation of the quality of life of patients and family/caregivers, and preferences regarding patient’s private health information, including genetic data. This registry should be dynamic and keep track of any diagnostic change if new evidence arises. Recently, a national registry for congenital anomalies (RENACH) was established [52]. A similar model can be implemented, with input from clinicians as well as from patients and families.
- Proposal 2. To elicit social preferences related to healthcare and financial coverage of RDs using qualitative methods with the general population, patient support groups, scientific societies, decision-makers, and other stakeholders. This information would provide a basis to adjust the existing prioritization algorithm for coverage in the National Health Care system for RD specific needs, taking into consideration the public opinion in the setting of national healthcare priorities [53, 54].
- Proposal 3. To improve access to clinical genetic services by increasing the number of providers in clinical/medical genetics, recognizing the specialty of clinical laboratory genetics, promoting training on RDs among primary care health teams to improve diagnostic suspicion and creating programs in genetic counseling for nurses, midwives, and other certified health professionals. To adequately serve the geographically dispersed population, a national interconnected network of clinical services for RDs should be established that can take advantage of existing public Telemedicine. A free public information portal of RD should be established supported by the Ministry of Health to improve knowledge among people.
- Proposal 4. To improve the performance of the healthcare system in the procurement of drugs and medical devices for RDs. It is essential to encourage regional cooperation in price negotiation, increase purchasing power, and enhance competition among pharmaceutical sellers. An example of these types of arrangements is the WHO/PAHO Strategic Fund, a mechanism to facilitate the acquisition of strategic health supplies for the Latin America region [55]. In this context, efforts could be made to include drugs associated with RDs in the Strategic Fund list of products and to purchase them through this mechanism.
- Proposal 5. To promote and develop local and international research partnerships for scientific and clinical collaboration. An obvious opportunity exists for synergy between research groups focused on RDs and normal human genetic variation to generate an integrated Chilean database of genomic variants. Work is progressing to move towards that goal. The newly established Ministry of Science, Technology, Knowledge, and Innovation [46] is expected to promote the growth and development of sciences and funding; we propose the establishment of specific programs for RDs. Regarding clinical trials, the legislators are considering a modification of the RSL, to promote the development of clinical trials in Chile, reducing the barriers but protecting the patients. All relevant stakeholders, clinical, scientific, political, and patients, should take part in this conversation.
- Proposal 6. To promote and facilitate the creation of a Latin-American cooperation network, to encourage the development, establishment, and dissemination of knowledge and new mechanisms for the diagnosis, treatment, and follow-up of RD patients, as well as the implementation of networks of sample and data banks at a regional level, similar to EURORDIS-Rare Diseases-Europe [56].